Jean-Sébastien Garrigue
Keine laufenden Positionen mehr
Profil
Jean-Sébastien Garrigue worked as the Director of Research & Pharmaceutical Development at Novagali Pharma SA from 2009 to 2011.
He holds an MBA from Université Paris 1.
Panthéon-Sorbonne, a doctorate, and a graduate degree from Université de Paris XI Paris Sud.
Ehemalige bekannte Positionen von Jean-Sébastien Garrigue
Unternehmen | Position | Ende |
---|---|---|
Novagali Pharma SA
Novagali Pharma SA Pharmaceuticals: MajorHealth Technology Novagali Pharma SA specializes in research, development and marketing of ophthalmic drugs. Their product pipeline includes products at various stages of development, which address diseases encountered at the three different segment levels of the eye which are surface, anterior and posterior segments. Some of these diseases are dry eye, allergy, glaucoma and retinopathies. Their formulations are based on their technology platforms Novasorb and Eyeject, which optimize bioavailability of drugs as well as safety and comfort for the patient. The company was founded on August 8, 2000 and is headquartered in Evry, France. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Jean-Sébastien Garrigue
Université Paris 1 Panthéon-Sorbonne | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Novagali Pharma SA
Novagali Pharma SA Pharmaceuticals: MajorHealth Technology Novagali Pharma SA specializes in research, development and marketing of ophthalmic drugs. Their product pipeline includes products at various stages of development, which address diseases encountered at the three different segment levels of the eye which are surface, anterior and posterior segments. Some of these diseases are dry eye, allergy, glaucoma and retinopathies. Their formulations are based on their technology platforms Novasorb and Eyeject, which optimize bioavailability of drugs as well as safety and comfort for the patient. The company was founded on August 8, 2000 and is headquartered in Evry, France. | Health Technology |
Université de Paris XI Paris Sud | Consumer Services |